“The increase in the supply of raw materials in the supply chain will take longer than expected,” Pfizer’s spokeswoman confirmed. “And it’s important to point out that the results of the clinical trials came later than the preliminary projections,” she added, suggesting that the first information on the delivery of one hundred million doses was only an estimate from the first half of November. At that time, however, production had not yet been secured by the end of the year.
–
“We’re late,” a source involved in vaccine development told the paper. “Some of the first batches of raw materials did not meet the standards. But we solved it by not fulfilling this year’s planned deliveries. ”He did not say which components were involved. Pfizer receives raw materials from suppliers in Europe and the USA.
–
The increase in the supply of these ingredients proved to be a problem last month at a time when the company was waiting for the results of clinical trials that showed 95% effectiveness on a sample of 44,000 people, the paper wrote. And he mentioned that usually pharmaceutical companies are waiting for the results of the third phase of clinical trials and approval for use by the relevant drug authorities, so the start of production is slower and more time.
–
“In this case, everything happened at once,” added the above-mentioned person familiar with Pfizer’s vaccine development: “We started creating a supply chain in March, when the vaccine was just being developed. That has no precedent. “
–
The new type of mRNA vaccine contains parts of RNA with viral genetic information that describe a protein that binds to infected cells. The cells in the vaccinated body then begin to produce this protein, and because it is foreign, the immune system responds to it and makes antibodies that target it. Then he is able to fight the virus that uses it.
–
But Pfizer still expects to produce and deliver more than 1.3 billion batches next year. So far, the co-vaccine Pfizer and BioNTech has been approved for use in the United Kingdom, which has ordered 40 million doses to vaccinate 20 million people because the vaccine is given in two doses. The government in London expected to receive ten million benefits this year, but now it is expected to be between four and five million. According to the British Minister of Health Matt Hancock, vaccination will start as soon as it is produced in the Belgian factory Pfizer. According to him, eight hundred thousand doses should arrive in the coming days and several million by the end of the year.
–
The United States has ordered one hundred million benefits with an option of another half billion. The US Food and Drug Administration is currently reviewing the vaccine and should decide on its use in December.
–
The EU has ordered 200 million doses with an option for another 100 million and Japan 120 million doses.
—
